According to @mcuban, U.S. hospital cost inflation is driven by seven insurer-related risks: deductible credit risk, pre-authorization denial/delay float, physician/admin appeal costs, underpayments versus contracted rates, annually changing admin processing costs, consultant spend tied to these issues, and dominance by certain networks that set rules; on the hospital side, five responses amplify prices: facility fees, list-price overcharges for later negotiation, 340B abuses, site-neutrality arbitrage, and underpaying clinicians (Source: @mcuban on X, Nov 20, 2025). He adds some hospitals can be profitable at Medicare/Medicaid rates if expenses are aligned to expected revenue, indicating margins need not rely on outsized commercial pricing alone (Source: @mcuban on X, Nov 20, 2025). For traders, the thread spotlights reimbursement and pricing pressure vectors—pre-authorization practices, contracted-rate underpayments, facility fees, site-neutral reforms, and 340B oversight—that map to revenue/margin risk for managed care carriers and hospital operators (e.g., UNH, HUM, ELV, CI, CVS; HCA, THC, UHS) based on the author’s claims (Source: @mcuban on X, Nov 20, 2025). Near term, monitoring headlines or policy movement around facility fees, site-neutrality, and 340B could be pivotal for positioning in these equities per the issues flagged by the author (Source: @mcuban on X, Nov 20, 2025).